August 18, 2010 |
A Philadelphia Common Pleas Court jury said Wednesday that two women's breast cancers were not linked to Wyeth's menopause drug, Prempro. After less than four hours of deliberation, the jury rejected claims by Sharon Buxley, 66, a Tennessee resident formerly of Allentown, and Joy Henry, 75, of Harrisburg, that the hormone-replacement therapy helped cause their cancers. The jury found that Prempro was "not a factual cause" in the development of the breast cancer. The plaintiffs argued during the four-week trial before Common Pleas Court Judge James Murray Lynn that Pfizer Inc.'s Wyeth subsidiary knew the treatment could promote the growth of cancer and should be held legally liable.
November 24, 2009 |
Pfizer Inc. has been hit with more than $100 million in two punitive-damage awards - one decided and the other unsealed yesterday - from Philadelphia juries. Both cases involve Prempro, a hormone-replacement drug made by Wyeth, which recently was acquired by Pfizer. Plaintiffs said the drug was linked to their breast cancer. The total includes $28 million awarded yesterday to Donna Kendall of Decatur, Ill. In the second case, Philadelphia Common Pleas Court Judge Sandra Moss yesterday unsealed a verdict reached earlier this year that awarded $75 million in punitive damages to another Illinois resident, Connie Barton, over her Prempro-linked breast cancer.
February 21, 2007 |
A Philadelphia jury blasted the drugmaker Wyeth yesterday for failing to warn a patient about breast-cancer risks of its hormone drug Prempro and awarded the Ohio woman and her husband $3 million in damages. It was the second - and biggest - loss in litigation over Prempro. Wyeth has headquarters in Madison, N.J., with pharmaceutical operations in Collegeville. It has won two Prempro cases, has settled at least one, and has three more trials scheduled for this year. Wyeth indicated it would appeal yesterday's verdict.
July 24, 2002 |
Wyeth said yesterday that its second-quarter profit jumped 26 percent, reflecting higher sales of key medicines such as the antidepressant Effexor. The Madison, N.J., drugmaker, which employs 4,000 in the Philadelphia region, said it would not forecast future earnings because of uncertainty over sales of its hormone replacement treatment, Prempro. A national study of 16,000 women has found that long-term use of Prempro, a combination of estrogen and progestin, may heighten the risk of breast cancer, heart disease, stroke and blood clots among women who take the medicine for as long as five years.
December 7, 2011 |
A Philadelphia jury Tuesday said pharmaceutical giant Pfizer Inc. must pay three women $72.6 million in compensatory damages because the menopause drugs they took gave them breast cancer. The Common Pleas Court jury will begin the punitive phase Friday and could last two weeks, but it might mean even larger awards for the women, who live or had lived in Pennsylvania. Jury awards in such cases can be reduced by judges or changed by appeals courts. "The plaintiffs were pleased with the phase one outcome, and they look forward to presenting phase two evidence beginning Friday," said attorney Tobi Millrood, a partner in the Conshohocken-based firm of Pogust, Braslow & Millrood L.L.C.
June 21, 2010 |
WASHINGTON - The U.S. Supreme Court is allowing a new trial in the case of a woman who got breast cancer after taking hormone replacement therapy and is seeking punitive damages against Wyeth Pharmaceuticals. The justices on Monday rejected Wyeth's attempt to block the trial because it is to be limited to punitive damages. Wyeth also wanted the high court to throw out $2.75 million compensatory damages that the woman, Donna Scroggin of Little Rock, Ark., won after suing Wyeth and Upjohn Co., another drugmaker.
February 23, 2010 |
A Philadelphia jury yesterday ordered Pfizer Inc.'s Wyeth unit to pay $9.45 million to an Alabama woman who claimed that the company's hormone-replacement drug caused her breast cancer. The Common Pleas Court jury awarded $3.25 million in compensatory damages and $6 million in punitive damages to Audrey Singleton, a retired school-bus driver from Chatom, Ala. The verdict also included $200,000 to Singleton's husband for loss of consortium. Pfizer, which is based in New York, said it would appeal the decision.
June 5, 2003 |
Days after a large federal study dealt the latest blow to its key hormone-replacement drug, Wyeth took out full-page advertisements in 180 newspapers to reach physicians and women about its hormone-therapy treatments. The ads, which appeared in newspapers in 20 cities, including The Inquirer, came after findings were published last week in the Journal of the American Medical Association that long-term use of Prempro, an estrogen-progestin hormone treatment, doubled the risk of dementia in women 65 and older.
July 13, 2002 |
Wyeth may have thought all the bad news was behind it when the pharmaceutical company changed its name from American Home Products Corp. in March, two months after completing $13.2 billion in settlements of its "fen-phen" diet-drug litigation. But the Madison, N.J., drugmaker, which employs 4,000 people in the Philadelphia region, got more bad news last week. A national study of the effects of one of its top-selling hormone replacement treatments, Prempro, was halted by the National Institutes of Health.